[Skip to Content]
Access to paid content on this site is currently suspended due to excessive activity being detected from your IP address 54.167.149.128. Please contact the publisher to request reinstatement.
[Skip to Content Landing]
Article
July 1982

Levodopa in Borderline Disorders

Author Affiliations

Department of Psychiatry New York University Medical Center New York, NY 10003 Harvey R. Redford, MD Department of Psychiatry Downstate Medical Center Brooklyn, NY 11203

Arch Gen Psychiatry. 1982;39(7):862. doi:10.1001/archpsyc.1982.04290070082018
Abstract

To the Editor.  —Many people believe that treatment of the borderline personality disorder is neither cost-effective nor clinically effective. In fact, this disorder usually seems to be refractory to a wide range of drugs, and the patients seem to experience most of the side effects and few of the benefits of the commonly used agents.1 We have dealt with the substance-abusing population in the New York metropolitan area and, true to DSM-III criteria, encountered within it a high proportion of patients with borderline personality.Observations of how the conditions of patients with borderline disorder respond to neuroleptic and antidepressant agents, and observations as to abuse substances of choice (along with the patients' reasons for preferring a particular drug) suggest that these patients are self-medicators.1 These factors and our clinical observations led us to suspect that many patients with borderline syndrome, especially those who exhibit symptoms of marked boredom, dysphoria,

First Page Preview View Large
First page PDF preview
First page PDF preview
×